Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3041
Cardiomyocyte apoptosis rate in the three groups.
Published 2024“…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
-
3042
Apoptosis ratio in three groups.
Published 2024“…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
-
3043
S1 File -
Published 2024“…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
-
3044
Cardiomyocyte apoptosis rate in the HF group.
Published 2024“…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
-
3045
-
3046
-
3047
-
3048
-
3049
-
3050
-
3051
-
3052
-
3053
Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation
Published 2024“…Although the development of DYRK1A inhibitors has significantly advanced in recent years, the selectivity of these drugs remains a critical challenge, potentially impeding further progress. …”
-
3054
-
3055
-
3056
-
3057
-
3058
-
3059
-
3060